Research Library › GHRH & Ghrelin-Receptor
IGF-1 LR3, short for Long R3 IGF-I, is a recombinant analog of human insulin-like growth factor 1 (IGF-1) with arginine substituted at position 3 and an N-terminal extension taken from porcine growth hormone. It was developed by researchers at CSIRO in Adelaide, Australia, including Geoffrey Francis and Francis Ballard, with patents held by GroPep, and was described in 1992. As of 22 Oct 2026 it is not approved as a drug in any country.
Key facts
| Type | Recombinant IGF-1 analog (fusion protein) |
|---|---|
| Derived from | Human IGF-1, with Arg at position 3 and an N-terminal extension from the first 11 amino acids of porcine growth hormone |
| First described | 1992, CSIRO Adelaide (Francis et al., Journal of Molecular Endocrinology) |
| Developed by | CSIRO, Adelaide (Geoffrey Francis, Francis Ballard); patents held by GroPep Ltd |
| Designed target | IGF-1 receptor, with reduced binding to IGF-binding proteins |
| Regulatory status (Oct 2026) | Not approved as a drug anywhere; named on WADA 2026 list (S2) |
Who developed it
IGF-1 LR3 was developed by scientists at the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Adelaide, Australia. Geoffrey Francis and Francis Ballard were among the authors of the 1992 paper that described the “Long” IGF-I analogs [1]. The Australian company GroPep held the related patents, including a 1987 filing on IGF-1 and IGF-2 analogs and a 1989 filing on growth hormone fusion proteins [2][3].
What it was designed to target
Natural IGF-1 is a 70-amino-acid growth factor produced mainly by the liver in response to growth hormone. In circulation and in cell culture, much of it is held by IGF-binding proteins, which limit how much reaches the IGF-1 receptor [1].
LR3 makes two changes to the human sequence. Arginine replaces the native residue at position 3 (the “R3”), and the first 11 amino acids of porcine growth hormone are fused to the front of the chain (the “Long”) [1][3]. Both changes were designed to reduce recognition by IGF-binding proteins while preserving binding to the IGF-1 receptor. The 1992 study concluded that, in a rat cell line, the analogs’ higher potency came mainly from weaker binding-protein interaction rather than stronger receptor binding [1].
Why it was created
GroPep’s patents listed the growth of cells in culture among the intended uses for the analogs, alongside human and veterinary applications [2][3]. The 1992 paper was framed as a structure-activity study: it used the new analogs to separate the roles of binding-protein affinity and receptor affinity in IGF-1 potency [1].
The parent molecule has a long history. A growth hormone-dependent blood factor that stimulated sulfate uptake by cartilage was described in 1957 and renamed somatomedin in 1972, later becoming known as IGF-1 [4][5].
Research timeline
- 1957: William Salmon and William Daughaday describe “sulfation factor,” later identified as IGF-1 [4].
- 1972: The name somatomedin is proposed [5].
- 1987: GroPep’s Australian priority filing for IGF-1 analogs [2].
- 1989: GroPep’s priority filing for growth hormone fusion proteins [3].
- 1992: CSIRO publishes the Long IGF-I analogs, including Long R3 IGF-I; the first GroPep U.S. patent is granted [1][2].
Regulatory status as of October 2026
As of 22 Oct 2026, IGF-1 LR3 is not approved as a drug in any country. The only FDA-approved IGF-1 medicine is mecasermin (Increlex), a recombinant copy of natural human IGF-1 approved in 2005 as an orphan drug for a rare pediatric indication [6].
IGF-1 analogs are named on the 2026 World Anti-Doping Agency Prohibited List under S2, prohibited at all times [7].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
What does LR3 stand for in IGF-1 LR3?
“L” stands for Long, referring to the 11-amino-acid extension from porcine growth hormone, and “R3” refers to the arginine placed at position 3 of the IGF-1 sequence.
Who developed IGF-1 LR3?
It was developed at CSIRO in Adelaide, Australia, by researchers including Geoffrey Francis and Francis Ballard, with patents held by GroPep. The analogs were published in 1992.
Is IGF-1 LR3 FDA approved?
No. As of 22 Oct 2026 IGF-1 LR3 is not approved as a drug anywhere. The only FDA-approved IGF-1 drug is mecasermin (Increlex).
How is IGF-1 LR3 different from IGF-1?
It has an arginine at position 3 and an N-terminal extension from porcine growth hormone, both designed to reduce binding to IGF-binding proteins.
Sources
- Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213–223. doi:10.1677/jme.0.0080213. PMID 1378742. Link
- Ballard FJ, Wallace JC, Wells JRE (GroPep Ltd). Peptide analogues of insulin-like growth factor 1 (IGF-1) or factor 2 (IGF-2). US Patent 5,164,370; Australian priority 24 Dec 1987; granted 17 Nov 1992. Link
- Wells JRE, King RM, Francis GL (GroPep Ltd). Growth hormone fusion proteins, methods of production, and methods of treatment. US Patent 5,330,971; priority 9 Jun 1989; granted 19 Jul 1994. Link
- Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957;49(6):825–836. PMID 13429201. Link
- Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, Van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature. 1972 Jan 14;235:107. doi:10.1038/235107a0. Link
- U.S. FDA, Drugs@FDA. BLA 021839, Increlex (mecasermin [rDNA origin]), Ipsen; original approval 30 Aug 2005 (orphan). Link
- World Anti-Doping Agency. 2026 Prohibited List (S2.2.4 growth hormone releasing factors; S2.3 growth factors). In force 1 Jan 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
